H. Lundbeck A/S today announced that the Board of Directors of the company has appointed Dr. Deborah Dunsire as new president and CEO of Lundbeck. Dr. Dunsire will take up her new position on 1 September 2018.
Trained as a medical doctor, Deborah Dunsire (56) is an experienced CEO who brings more than 30 years of clinical, commercial, and international management experience from the biotech and pharmaceutical industry, primarily in the fields of oncology and CNS, thus bridging a breadth of scientific and business experience. Her wealth of professional and executive experience includes positions as President and CEO of XTuit Pharmaceuticals, Inc., FORUM Pharmaceuticals Inc. and Millennium Pharmaceuticals, Inc.
“It is a great pleasure to announce that Deborah Dunsire will join Lundbeck as President and CEO,” says Lars Rasmussen, Chairman of Lundbeck’s Board of Directors. “She brings a wealth of highly successful R&D and commercial experiences including a robust knowledge and experience in neuroscience. She is a proven and highly passionate leader and has all the qualifications to take Lundbeck to the next level as a global leader within psychiatric and neurological disorders.”
Dr. Dunsire has lived in the U.S. since 1994, and grew up in South Africa where she graduated from University of the Witwatersrand, Johannesburg, in 1985. In connection with her new position, Dr. Dunsire plans to move to Denmark from the U.S.
“Lundbeck stands out in the industry as a global company with a great history of innovating in neuroscience, which is recognized to be one of the toughest research areas for the industry “, says Dr. Dunsire and continues “I am excited to bring my experience to help build an even stronger and brighter future for Lundbeck, patients, employees, partners and shareholders.”
From 1 September 2018, Anders Götzsche, interim CEO and CFO in Lundbeck will resume his position as CFO for the company.
“Anders has held the position as interim CEO since November 2017, and has together with the rest of management team done an excellent job in continuing the strong positive development that Lundbeck is having,” says Lars Rasmussen, Chairman of Lundbeck’s Board of Directors. “The Board will like to express gratitude for a job well done and we look forward to see Lundbeck continuing the positive development under the new management team.”
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).